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Canonical Wnt signalling is an osteoinductive signal that promotes bone repair through acceleration of osteogenic differentiation by
progenitors. Dkk-1 is a secreted inhibitor of canonical Wnt signalling and thus inhibits osteogenesis. To examine a potential
osteoinhibitory role of Dkk-1 in osteosarcoma (OS), we measured serum Dkk-1 in paediatric patients with OS (median age, 13.4
years) and found it to be significantly elevated. We also found that Dkk-1 was maximally expressed by the OS cells at the tumour
periphery and in vitro, Dkk-1 and RANKL are coexpressed by rapidly proliferating OS cells. Both Dkk-1 and conditioned media from
OS cells reduce osteogenesis by human mesenchymal cells and by immunodepletion of Dkk-1, or by adding a GSK3b inhibitor, the
effects of Dkk-1 were attenuated. In mice, we found that the expression of Dkk-1 from implanted tumours was similar to the human
tumour biopsies in that human Dkk-1 was present in the serum of recipient animals. These data demonstrate that systemic levels of
Dkk-1 are elevated in OS. Furthermore, the expression of Dkk-1 by the OS cells at the periphery of the tumour probably contributes
to its expansion by inhibiting repair of the surrounding bone. These data demonstrate that Dkk-1 may serve as a prognostic or
diagnostic marker for evaluation of OS and furthermore, immunodepletion of Dkk-1 or administration of GSK3b inhibitors could
represent an adjunct therapy for this disease.
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Mesenchymal stem cells (MSCs) from the bone marrow are
progenitors of osteoblasts, the cells that build and maintain bone
tissue. The process of osteoblast differentiation, and the subse-
quent repair of bone is driven by canonical Wingless (Wnt)
signalling within the MSC (Cadigan and Nusse, 1997; Kikuchi,
2000; Huelsken and Birchmeier, 2001; Pandur et al, 2002; Bain
et al, 2003; Rawadi et al, 2003; Bodine et al, 2004; Bennett et al,
2005; Gregory et al, 2005a,b; Holmen et al, 2005; Hartmann, 2006;
Krishnan et al, 2006).
In the canonical Wnt signalling pathway, Wnt ligands bind to
the transmembrane receptor frizzled (Frz) and the co-receptor
lipoprotein related proteins 5 and 6 (LRP-5/6) on the surface of the
target cell. Activation of Frz recruits the cytoplasmic-bridging
molecule, disheveled, so as to inhibit the action of glycogen
synthetase kinase-3b (GSK3b). Inhibition of GSK3b decreases
phosphorylation of b-catenin, preventing its degradation by the
ubiquitin-mediated pathway. The stabilised b-catenin acts on the
nucleus by activating TCF/LEF-mediated transcription of target
genes that elicit a variety of effects including induction of
differentiation and proliferation (Cadigan and Nusse, 1997;
Kikuchi, 2000; Huelsken and Birchmeier, 2001; Pandur et al, 2002).
The presence of Wnt signalling inhibitors such as Dkk-1 (Glinka
et al, 1998; Krupnik et al, 1999; Nusse, 2001; Mao et al, 2002;
Kawano and Kypta, 2003; Li et al, 2006; Morvan et al, 2006) can
disrupt the repair of bone and its secretion by tumours into the
bone can lead to irreparable damage to the tissue. Examples
include multiple myeloma (Tian et al, 2003) and some forms of
prostate cancer (Hall et al, 2005). Damage of the bone by
malignancy can increase the severity of the disease by providing
a permissive microenvironment for tumour growth and metastatic
events. In multiple myeloma, Dkk-1 is readily detectable in the
blood of individuals in the later stages of the disease who have
characteristic osteolytic bone lesions (Tian et al, 2003).
Given that high levels of Dkk-1 are also expressed by rapidly
dividing osteosarcoma (OS) cells in vitro (Gregory et al, 2003,
2005a,b), we measured the level of Dkk-1 in the serum of
paediatric patients with OS (median age, 13.4 years) and found it
to be significantly elevated when compared with healthy controls.
The aim of this study therefore, was to investigate the significance
of such a finding in OS. Dkk-1 and Receptor Activator for Nuclear
Factor-kB Ligand (RANKL) were found to be maximally expressed
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sby rapidly dividing OS cells in vitro and by cells at the periphery
of the solid tumour in vivo. Since Dkk-1 and RANKL inhibit
osteogenic differentiation and activate osteoclasts, respectively,
these proteins probably contribute to tumour expansion by
inhibiting repair of the surrounding bone while simultaneously
accelerating resorption. Employing in vitro assays, we examined
the possibility that immunodepletion of Dkk-1 or administration
of GSK3b inhibitors could represent an adjunct therapy for this
disease by improving osteogenic tissue repair adjacent to the
tumour.
MATERIALS AND METHODS
Human biomaterial acquisition
The handling and acquisition of human-derived biomaterials were
performed in accordance with the Institutional Review Boards and
Ethics Committees of Tulane University Hospital and Clinic (New
Orleans, LA, USA) and St Jude Children’s Hospital (Memphis, TN,
USA). The OS serum samples were acquired from the tissue bank
of St Jude Children’s Hospital, and the control group samples
were collected from unaffected individuals at Tulane University
Hospital and Clinic. Human MSCs were acquired from the Tulane
Adult MSC Distribution Core (Tulane University, New Orleans,
LA, USA) and cultured in accordance with their protocols.
ELISA assays
Frozen serum samples from newly diagnosed patients with OS
were acquired from St Jude Children’s Hospital under the
supervision of Dr N Daw and Dr E Horwitz. Serum samples from
unaffected individuals were drawn and prepared at Tulane
University Hospital and Clinic. Enzyme-linked immunosorbent
assays (ELISAs) were performed using a polyclonal duo set (R&D
Systems, Minneapolis, MN, USA, catalogue no. AF1096) consisting
of a goat anti-human Dkk-1 antibody and a biotinylated sample of
the same serum. Microtitre plates (Nunc Immunosorp, Rochester,
NY, USA) were coated with 100mlo fa1 mgml
 1 solution of the
capture antibody for 15h at 41C, then blocked for 2h at 21–251C
in PBST (phosphate-buffered saline containing 0.1% (v/v) Tween
20) containing 4% (v/v) bovine serum albumin. Samples were
diluted initially at 1:3 then up to 1:10 in PBST depending on
the levels of Dkk-1 in the sample. Plates were washed three times
prior to loading onto the plate in 100ml aliquots. Samples were
incubated for 15h at 41C in the plates, wells were then washed
three times in PBST. One hundred microlitres of a 0.5-mgml
 1
detection antibody was then added to each well followed by
incubation for 2h at 21–251C. The wells were then washed three
times in PBST, followed by addition of a 1:2000 dilution of
streptavidin-conjugated horseradish peroxidase (Pierce, Rockford,
IL, USA). After a final wash step, the wells were developed by
addition of 2,20-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)
or tetramethlybenzidine. After stopping the reactions with 5 M
NaOH or 2 M H2SO4, respectively (Sigma, Poole, Dorset, UK), wells
were read at 405 or 450nm by automated plate reader (Fluostar;
BMG Labtech, Durham, NC, USA). The linear range of the assay
was 0.2–20ngml
 1 and maximum variation between assays was
5% of the mean.
Histology and immunocytochemistry
Osteosarcoma tumours, synthetic tumour constructs or monolayer
cells were fixed in formalin and processed as paraffin blocks if
necessary. For histology, 8-mm sections were prepared, deparaffi-
nised and rehydrated, then stained with haematoxylin–eosin
(Sigma). For immunohistochemistry, after an acidic antigen
retrieval step (R&D Systems), sections were blocked and incubated
in the presence of a 1:800 dilution of goat anti-human Dkk-1 or
monoclonal anti-RANKL antibody (R&D Systems). Monolayer
cultures were directly subjected to immunocytochemistry after
fixation. Alexafluor 594 or 488 conjugated secondary (Invitrogen,
Carlsbad, CA, USA) antibodies were employed to detect antigen
binding.
Alkaline phosphatase assays
Alkaline phosphatase assays were performed on monolayers in six-
well format as previously described (Gunn et al, 2005). Briefly,
MSCs were seeded at a density of 5000 cells per cm
2 and cultured
for 10 days in osteoinductive media. Osteoinductive media
consisted of alpha MEM containing 20% (v/v) fetal bovine serum
(Atlanta Biologicals, Norcross, GA, USA), 100unitml
 1 penicillin,
1mgml
 1 streptomycin, 4mML -glutamine, 5mM b-glyceropho-
sphate (Sigma), 100mgml
 1 ascorbate-2-phosphate (Sigma) and
the appropriate concentration of Dkk-1 or bromo-indirubin-
30-mono-oxime (BIO; Calbiochem, La Jolla, CA, USA) suspended
in dimethylsulphoxide (Sigma). Unless otherwise stated, all cell
culture reagents were purchased from Invitrogen. Recombinant
human Dkk-1 preparation was carried out as previously described
from a stably expressing COS cell line (Gunn et al, 2005).
Mineralisation assays
All reagents were purchased from Sigma. In the six-well format,
MSCs were cultured at high density (500 cells per cm
2) in the
presence of osteoinductive media, but in the absence of steroids,
for 15 days with or without 500ngml
 1 recombinant Dkk-1.
Thereafter, the media was transferred to osteoinductive media with
10
 8 M dexamethasone for a further 7 days. The monolayers were
then washed in PBS, fixed for 10min in phosphate-buffered
formalin, then stained with the calcium-binding dye, Alizarin Red
S. Monolayers were photographed using a Nikon Eclipse TE200
inverted microscope fitted with a Nikon DXM1200F digital camera.
Cell counting assays
Cells were counted based on nucleic intercalation of a fluorescent
dye (CyQuant, Invitrogen). Assays were performed as previously
described (Gregory et al, 2003, 2005b).
Western blotting
Western blots were performed on Triton X-100 (Sigma) insoluble
extracts of cells using the goat anti-human Dkk-1 or monoclonal
anti RANKL antibody (R&D Systems). Controls for actin and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were em-
ployed as previously described (Gregory et al, 2005b).
Immunoaffinity depletion
The inhibitor Dkk-1 was depleted from the medium by antibody
incubation and protein A/G-mediated depletion as previously
described (Gregory et al, 2003). Immunodepletion was carried out
using the rabbit anti-Dkk-1 polyclonal antiserum described in
Gregory et al (2003) or the goat anti-Dkk-1 polyclonal acquired
from R&D Systems. Protein A (for rabbit) and protein G (for goat)
were conjugated to sepharose beads (Amersham Pharmacia
Biotech, Piscataway, NJ, USA).
Cell labelling
The lentiviral construct encoding the dsRed fluorescent protein
coupled to the mitochondrial localisation sequence of human
cytochrome c oxidase subunit VIII was prepared using standard
protocols by virus core facility at Louisiana State University viral
vector core (Marino et al, 2003; Zhang et al, 2004). Proliferating
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of 80 in the presence of 9mgml
 1 polybrene for 18h. After 4 days,
approximately 50% of the cells expressed the fluorescent protein.
Expressing cells were selected by fluorescent-activated cell sorting
(Facsvantage SE; Becton Dickinson, Franklin Lakes, NJ, USA).
Constructs
Labelled cells were suspended in 1ml of a 2  reconstitution of
dried human plasma (Sigma) and mixed with an equal volume of
thromboplastin C (Plastinex; Fisher Life Sciences, Pittsburg, PA,
USA). The mixture was transferred to a 10mm 20mm chamber
slide for gelling. Clotting was allowed to proceed for 2–4h, and
then the appropriate experimental medium preparation was added
to cover the solid construct until implantation.
Implantation
Experiments were conducted in accordance with Tulane University
Animal Use and Care Committee regulations. Fibrin constructs
were implanted subcutaneously between the scapulae of anaes-
thetised nude mice. A 10-mm incision was made longitudinally
between the scapulae, and a small cavity was made between the
dermis of the skin and the fascia below to accommodate the
constructs, which were 10mm
2. The incision was then closed by
2–3 sutures, and sealed (Vetbond; 3M, St Paul, MN, USA). After 5
days, the sutures were removed. Seven days thereafter, the animals
were placed under anaesthesia, euthanised by cardiac exsanguina-
tion, and serum was prepared from the blood. The implants were
removed for genomic DNA extraction. Genomic DNA was
extracted from the tissue by phenol chloroform extraction (Trizol,
Invitrogen) and subjected to quantitative real-time PCR for the
dsRed gene using the following primers: forward, ACTACAA
GAAGCTGTCCTTCC and reverse, TTCACGCCGATGAACTT
CACC. Reactions were cycled on an ABI PRISM 7700 Sequence
Detector (Applied Biosystems) for 40 cycles with the annealing
temperature set to 601C. Products were detected by fluorescence
intercalation (SYBR Green, Applied Biosystems) and validated by
gel electrophoresis and melting curve analysis.
RESULTS
We measured the levels of Dkk-1 in the serum of newly diagnosed
individuals with OS by ELISA and found that the mean levels were
elevated (Po0.00002, Mann–Whitney U-test, two tails) in affected
individuals (range: 16.84–2210.14ngml
 1, mean 191.91ngml
 1,
median 90.53ngml
 1) when compared to unaffected individuals
(range: 2.28–43.38ngml
 1, mean 21.66ngml
 1, median
19.67ngml
 1). Although the control group (n¼12) was smaller
than the OS group (n¼37), and the median age of the unaffected
individuals was slightly higher (by approximately 7 years), the
control Dkk-1 values were similar to the normal levels reported by
Tian et al (2003), who demonstrated that elevated levels of serum
Dkk-1 were coincident with the osteolytic lesions seen in most
cases of multiple myeloma (Figure 1A). The Dkk-1 levels in the
affected individuals were somewhat higher than those documented
in the study by Tian et al (2003) with the highest levels in the
micromolar range. Immunohistochemical staining of excised
tumour biopsies demonstrated that Dkk-1 was expressed maxi-
mally at the periphery of the tumour, adjacent to the hosts’ bone
tissue (Figure 1B). Upon histological examination of serial sections
of excised tumour tissue, the areas that stained most intensely for
Dkk-1 were accompanied by extensive remodelling. The border of
the adjacent osteoid was irregular, with frequent penetration of
many tumour cells, consistent with a destructive OS (Figure 1C).
The expression of Dkk-1 by two OS cell lines; MG63, a well-
characterised osteogenic sarcoma and LS1, a cell line derived from
an excised OS, was examined in more detail in tissue culture
experiments. Dkk-1 was found to be maximally secreted by cells
rapidly proliferating in sparsely populated monolayers but was
significantly reduced as proliferation slowed and the monolayer
became more confluent (Figures 1D and E). Interestingly, Dkk-1
expression in the higher density monolayers was confined to a
small fraction of cells that were clearly in the metaphase of cell
division (Figure 1E). Also, the potent upregulator of osteoclast
activity, RANKL (Blair et al, 2006) mirrored the expression of
Dkk-1 in OS cells, but it was exclusively detected as the membrane
bound form rather than the secreted form (Figures 1F and G). On
the basis of these observations, we hypothesised that the
expression of Dkk-1 and RANKL at the periphery of the tumour
was necessary for osteogenic remodelling as the tumour expands.
The presence of high levels of Dkk-1 and RANKL facilitate
expansion by allowing the proliferative cells at the periphery of the
tumour to accelerate bone resorption through expression of
RANKL while inhibiting osteoid repair through the action of
Dkk-1.
The putative osteoinhibitory effect of recombinant Dkk-1 was
tested in a tissue culture model of osteogenic differentiation by
human primary MSCs. At concentrations equivalent to those
measured in OS patients, Dkk-1 inhibited the expression of the
osteogenic marker, alkaline phosphatase, by MSCs in a dose-
dependent manner when added to osteogenic cultures (Figure 2A).
The effect was observed in MSCs from three donors and pooled
murine MSCs. In two donors (Figure 2A), MSCs cultured directly
from bone spicules (red) were more resistant to Dkk-1 than those
cultured from the fluid component of the marrow (black),
suggesting that the MSCs were probably osteogenically precondi-
tioned by the niche of the bone tissue. The observation that serum
alkaline phosphatase is occasionally upregulated in OS patients,
suggests that Dkk-1 acts to prevent differentiation of progenitor
cells, but does not affect the release of alkaline phosphatase from
preexisting osteoblasts at sites of bone remodelling. To examine
the effect of Dkk-1 on late-stage osteogenesis by MSCs, the cells
were cultured in with b-glycerophosphate and ascorbic acid for 15
days, and then in the presence of dexamethasone for a further 7
days to induce calcification. The monolayers were then fixed and
stained with the calcium-binding dye, Alizarin Red S. The presence
of 500ngml
 1 Dkk-1 in the 15-day preincubation step inhibited
calcification of the monolayers when compared with controls
(Figure 2B).
When media were conditioned by MG-63 OS cells and added to
osteogenic cultures of MSCs, osteogenic inhibition occurred
(Figure 2D), and this effect was attenuated upon immunodepletion
of Dkk-1 from the medium (Figures 2C and D). Dkk-1 inhibits the
Wnt pathway by sequestering the Wnt co-receptor, LRP6 and
preventing the Wnt-induced coalescence of Frz and LRP6 at the
membrane. The downstream effect of the LRP6/Wnt/Frz complex
is to inhibit GSK3b, reduce phosphorylation of b-catenin and
prevent its degradation by the proteosomal machinery. Stabilised
b-catenin complexes with TCF/LEF mediates transcription of
target genes, in this case, osteogenic genes. The presence of a
pharmaceutical inhibitor of GSK3b would be predicted to elicit the
same effect as Wnt signalling, irrespective of the level of Dkk-1 in
the system. Osteogenic cultures were therefore prepared in the
presence of Dkk-1 with or without the GSK3b inhibitor, BIO. The
presence of BIO reduced the osteoinhibitory effect of Dkk-1
(Figure 2E). Since Wnt signalling has been implicated in the
induction of oncogenesis, we tested the effect of escalating doses of
BIO on MG-63 and LS-1 cell proliferation. At the concentrations
tested, there was no significant induction of proliferation by BIO
(Figure 2F).
We established an OS model to recapitulate some of the effects
of Dkk-1 and OS in vivo. MG-63 cells were labelled by lentiviral
transduction of a fusion gene combining the mitochondrial
localisation sequence of cytochrome c oxidase with the fluorescent
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presence of clotted human plasma, after 24–48h, the cells formed
tumour spheroids that ranged from approximately 10 to 5000 cells
in diameter within the fibrin gel (Figure 3C). Smaller spheroids
expressed Dkk-1 throughout, but the larger structures adopted an
expression pattern for Dkk-1 that mimicked the tumour biopsies
(Figure 3D) with the maximal level of expression at the periphery.
To examine Dkk-1 expression by OS cells in vivo, fibrin constructs
containing 1 million and 10 million labelled MG63 cells were
implanted in nude mice against the upper thoracic vertebrae. After
1 week, the constructs were clearly visible by live animal
fluorescent imaging (Figure 4A). Furthermore, human Dkk-1
could be detected in the blood of implanted animals when assayed
by ELISA (Figure 4B) and the level of circulating Dkk-1 correlated
with the number of surviving cells in the construct. After 2 and 4
weeks post implantation, the number of MG63 cells present in the
recipients had reduced resulting in a concomitant reduction of
systemic Dkk-1 (data not shown). The reason for the reduced
viability of the cells over extended implantation periods is unclear,
but macrophage mediated destruction of implants in immuno-
compromised mice has been reported in the literature (Xia et al,
2004). In spite of the hosts’ response to the implanted cells, human
Dkk-1 could be detected in the blood of the recipient mice,
demonstrating that tumour-derived Dkk-1 escapes into the blood
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Figure 1 (A) Scatter plot of the circulating Dkk-1 levels in OS patients and unaffected individuals. Measurements were performed by ELISA. The
difference between Dkk-1 levels in patients vs healthy controls was significant (Po0.00002) when compared using a Mann–Whitney U-test. (B) A sectioned
OS immunostained for the detection of Dkk-1 (red). Dkk-1 expression is maximal at the border zone between the osteoid tissue (green autofluorescence)
and the tumour cells (white dotted line). Nuclei are stained with 40-6-diamidino-2-phenylindole (DAPI; blue). (C) The OS is sectioned and stained with
haematoxylin–eosin. The osteoid (o) is infiltrated with tumour cells (t), resulting in rough zones of osteoid remodelling (arrowed). A high-power micrograph
of a zone of osteoid degradation is provided on the right. (D) Secretion of Dkk-1 by rapidly dividing, low-density cultures (log) and slowly dividing confluent
cultures (slow) of MG63 and LS1 OS cells. Measurements were made by ELISA, values represent the mean (n¼6), and error bars represent s.d. P-values
were calculated by two-tailed Student’s t-test. (E) Monolayers of MG63 cells at high (slow) and low (log) density immunostained for Dkk-1. Note that
staining is maximal in the low-density cultures and in the high-density cultures, Dkk-1 staining is confined to those cells undergoing mitosis (arrowed). The
DNA is stained with DAPI (blue). (F) Western blot of membrane isolates derived from MG63 and LS1 OS cells. The control lanes (upper) were
simultaneously incubated with an anti-b-actin and anti-GAPDH antibodies since enrichment for insoluble, membrane bound, b-actin confirms that the
membranes have been efficiently recovered at the expense of cytosolic components such as GAPDH. Membrane-bound RANKL was detected on the same
stripped blot (lower) with an anti-RANKL antibody. (G) Monolayers of nonpermeabilised MG63 cells at high (slow) and low (log) density immunostained for
RANKL. Note that staining is maximal in the low-density cultures and punctuates in the high-density cultures. The DNA is stained with DAPI (blue).
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sstream. It is unclear at this point whether the elevated systemic
Dkk-1 in OS patients is derived solely from the tumour, since the
human Dkk-1 circulating in the blood of recipient mice was much
lower than the mean levels detected in the blood of the human OS
patients. It is possible, however, that the host tissue interacts with
the tumour, resulting in upregulation of the expression of Dkk-1, a
phenomenon observed in the case of multiple myeloma (Gunn
et al, 2005; Corre et al, 2007). The host microenvironment in the
patients may be more readily affected by the tumour than the
surrounding mouse tissue accounting for the reduced levels of
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Figure 2 (A) Osteogenic differentiation of MSCs in the presence of Dkk-1. Results from cells derived from three human donors and pooled murine
donors are presented. Osteogenic differentiation is presented as a function of membrane ALP activity, an early marker of osteogenesis. Measurements are
normalised to control levels of activity, designated 1.0. The black lines represent MSCs prepared from the fluid component of bone marrow, and the red
lines represent MSCs prepared from bone spicules filtered from the aspirates. Dkk-1 exposure causes a dose-dependent inhibition of alkaline phosphatase
activity. (B) Alizarin Red stained, long-term cultures of osteogenic MSCs in the presence and absence of Dkk-1. Calcium detection by Alizarin Red S
demonstrates that Dkk-1 inhibits mineralisation of the cultures. (C) Immunodepletion of Dkk-1 from MG63 OS conditioned medium through incubation
with a polyclonal antibody against Dkk-1. The Dkk-1–antibody complexes were removed from the medium by protein A affinity chromatography, then the
medium was assayed by ELISA. (D) Osteogenic differentiation by MSCs in the presence of nondepleted and Dkk-1 immunodepleted conditioned medium
from MG63 OS cells. Representative results from one out of three donors are presented. Measurements were achieved by ALP assay, values represent the
mean (n¼6), and error bars represent s.d. P-values were calculated by two-tailed Student’s t-test. (E) Osteogenic differentiation by MSCs in the presence of
Dkk-1 and with or without the GSK3b inhibitor BIO. (F) The effect of a range of BIO doses on the proliferation of OS cells. Cell numbers were evaluated by
fluorescent nucleic acid intercalation assay.
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any rate, the presence of OS cells in both humans and the recipient
mice resulted in elevated circulating human Dkk-1, suggesting that
the molecule could represent a valuable diagnostic tool. The
correlation of tumour load with Dkk-1 levels also suggests that the
assay also has potential for measuring the relative size and severity
of such tumours.
DISCUSSION
These data strongly suggest that the canonical Wnt inhibitor Dkk-1
is highly expressed by OS tumours at levels that become
systemically detectable in humans. Furthermore, the in vivo data
demonstrate that the level of Dkk-1 detectable in blood is
proportional to the number of surviving OS cells in the tumour.
Assays of Dkk-1 secretion could therefore represent a useful
diagnostic and prognostic tool for the evaluation of OS patients.
Dkk-1 is also upregulated by other malignant cell lines (Wirths
et al, 2003; Forget et al, 2007), suggesting that serum Dkk-1
measurements may be useful for the evaluation of other types of
malignancy, but the significance of Dkk-1 expression is not
presently clear in tumours that do not affect bone. Although the
data presented here demonstrate that Dkk-1 may contribute to OS
pathogenesis by preventing repair of the surrounding osteoid as
the tumour expands, Dkk-1 may act in an autocrine manner on the
tumour cells too. Noteworthy are the observations that exposure of
MG63 and LS1 OS cells to high concentrations of BIO reduces
proliferation (Figure 2F), and immunosequestration of Dkk-1
transiently slowed the proliferation of MG63 cells in vitro (Gregory
et al, 2003). It is unlikely that Dkk-1 can solely act as a mitogen,
but its presence at a critical threshold may serve as a checkpoint
that permits proliferation of OS cells. One attractive hypothesis is
that Dkk-1 has to be present to prevent inappropriate differentia-
tion during a rapid burst of mitosis and a collateral effect of this is
to prevent osteoid repair by progenitor cells.
In instances of osteolytic tumours, the presence of Dkk-1 would
be predicted to exacerbate lesion formation through inhibition of
Wnt-dependent osteogenesis. This certainly seems probable since
a recent study has demonstrated that prostate tumours-expressing
high levels of Dkk-1 produce more extensive local bone destruc-
tion compared to controls that express lower levels (Hall et al,
2005). Reducing the osteoinhibitory effects of Dkk-1 would
therefore be predicted to reduce local bone damage, and as a
result, probably reduce the expansion of the tumour. This could be
achieved by pharmaceutical inhibition of GSK3b, by inhibition of
the proteasomal degradation pathway, or by antibody-mediated
sequestration of Dkk-1. The osteoinductive properties of GSK3b
inhibitors have been demonstrated both in vivo and in vitro by
numerous investigators (Gregory et al, 2006), proteasomal
inhibitors have been shown to reduce Dkk-1 and RANKL levels
(Terpos et al, 2006), and the benefits of administration of an
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Figure 4 (A) Live animal fluorescence imaging of an implanted construct containing labelled MG63 OS cells. (B) Evaluation of human Dkk-1 levels in the
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santi-Dkk-1 antibody have recently been demonstrated in a murine
model of multiple myeloma (Yaccoby et al, 2007). However, it
remains to be seen whether the induction of Wnt signalling either
by GSK3b inhibition, or by antibody administration may affect the
metastatic potential of OS cells since Wnt signalling and/or
b-catenin upregulation has been shown to be a key regulator of
migration in prostate tumours, multiple myeloma cells and also in
OS cells (Iwaya et al, 2003; Qiang et al, 2005; Hall et al, 2006).
Although we did not detect signs of pulmonary metastasis in this
study, further investigation employing highly metastatic OS cell
lines should be performed in future work.
Irrespective of concerns regarding the use and safety of GSK3b
inhibitors, proteasome inhibitors or antibodies directed towards
Dkk-1 as an adjunct treatment for OS, the diagnostic utility of serum
Dkk-1 is strongly supported by this study. Since tumour-derived
Dkk-1 was present in the blood of mice at levels proportional to the
number of surviving tumour cells, Dkk-1 may serve as a powerful and
noninvasive tool for the evaluation of patients with OS.
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